Also found in: Acronyms, Encyclopedia, Wikipedia.
bacterial intravenous protein
behavioural intervention plan
Bezafibrate Infarction Prevention study
bismuth iodoform paraffin
biparietal diameter, see there
bleomycin, ifosfamide, platinol (a chemotherapy regimen)
Books In Print
bronchiolitis obliterans with usual interstitial pneumonitis
Bezafibrate Infarction Prevention study. A trial that asked whether increasing HDL-C and reducing triglycerides (TGs) using bezafibrate would reduce acute MIs and sudden death linked to coronary atherosclerosis.
With bezafibrate, HDL-C increased by 18%, TGs decreased by 21%; acute MIs or sudden death occurred in 14% of bezafibrate patients vs 15% of placebo patients; in patients with high baseline TGs, there was a 40% reduction in cumulative probability of MI or sudden death in bezafibrate patients.
Randomised, double-blind, placebo-controlled; 3090 patients—1548 bezafibrate, 1542 placebo, mean age 60, with previous MI or stable angina and a certain lipid profile.
BIP enrollee lipid profile
Total serum cholesterol 180–250 mg/dl, HDL-C ≤ 45 mg/ dl, TGs ≤ 300 mg/dl and LDL-C ≤ 180 mg/dl or ≤ 160 mg/dl for patients < age 50.